Literature DB >> 16901392

The "new" era of oral antineoplastic drug therapy: revisiting "old" concerns.

Maurie Markman1.   

Abstract

Mesh：

Substances：

Year:  2006        PMID： 16901392     DOI： 10.1007/s11912-006-0051-3

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


× No keyword cloud information.
  11 in total

1.  Viewing ovarian cancer as a "chronic disease": what exactly does this mean?

Authors:  Maurie Markman
Journal:  Gynecol Oncol       Date:  2005-10-14       Impact factor: 5.482

Review 2.  Adherence to medication.

Authors:  Lars Osterberg; Terrence Blaschke
Journal:  N Engl J Med       Date:  2005-08-04       Impact factor: 91.245

3.  Maintenance therapy to suppress micrometastasis: the new challenge for adjuvant cancer treatment.

Authors:  Richard J Epstein
Journal:  Clin Cancer Res       Date:  2005-08-01       Impact factor: 12.531

4.  Integration of chemotherapy into combined modality treatment of solid tumors VII. Adenocarcinoma of the breast.

Authors:  S K Carter
Journal:  Cancer Treat Rev       Date:  1976-09       Impact factor: 12.111

5.  Helping patients follow prescribed treatment: clinical applications.

Authors:  R Brian Haynes; Heather P McDonald; Amit X Garg
Journal:  JAMA       Date:  2002-12-11       Impact factor: 56.272

Review 6.  Modulation of oral drug bioavailability: from preclinical mechanism to therapeutic application.

Authors:  Isa E L M Kuppens; P Breedveld; J H Beijnen; J H M Schellens
Journal:  Cancer Invest       Date:  2005       Impact factor: 2.176

7.  Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer.

Authors:  T Browder; C E Butterfield; B M Kräling; B Shi; B Marshall; M S O'Reilly; J Folkman
Journal:  Cancer Res       Date:  2000-04-01       Impact factor: 12.701

8.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

9.  Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial.

Authors:  Maurie Markman; P Y Liu; Sharon Wilczynski; Bradley Monk; Larry J Copeland; Ronald D Alvarez; Caroline Jiang; David Alberts
Journal:  J Clin Oncol       Date:  2003-07-01       Impact factor: 44.544

10.  Hospital admissions resulting from preventable adverse drug reactions.

Authors:  Patrick J McDonnell; Michael R Jacobs
Journal:  Ann Pharmacother       Date:  2002-09       Impact factor: 3.154
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.